48 Results for "

Imatinib Acid

" in MedChemExpress (MCE) Product Catalog:
Products (48)

48 Results for "Imatinib Acid" in MCE Product Catalog:

Cat. No.: HY-135638
CAS No.: 2741007-77-0
Purity:  99.73%
Imatinib Acid is an analogue of Imatinib (HY-15463) .
loading...
    loading...
127
127 Publications Verification
Cat. No.: HY-15463
CAS No.: 152459-95-5
Purity:  99.95%
Synonyms: STI571; CGP-57148B
Research Areas:  

Cancer

Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
loading...
    loading...
127
127 Publications Verification
Cat. No.: HY-50946
CAS No.: 220127-57-1
Synonyms: STI571 Mesylate; CGP-57148B Mesylate
Imatinib Mesylate (STI571 Mesylate) is an orally active tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-12494
CAS No.: 1361030-48-9
Purity:  99.64%
Target:  

TAM Receptor FLT3

Research Areas:  

Neurological Disease Cancer

LDC1267 is a AXL/TAM/FLT3 inhibitor with IC50 values of 42 nM, 130 nM, and 63 nM against AXL, MERTK, and TYRO3, respectively. LDC1267 blocks GAS6-induced AXL phosphorylation and the downstream AKT/ERK1/2 signaling pathway. LDC1267 inhibits cancer cell proliferation, colony formation, and glioblastoma cell invasion, without causing obvious impairment of cytotoxic autophagic flux. LDC1267 exerts a synergistic effect when used in combination with Imatinib (HY-15463) in chronic myeloid leukemia models. LDC1267 can be widely applied in studies related to glioblastoma and chronic myeloid leukemia .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-G0017
CAS No.: 404844-02-6
Synonyms: NorImatinib; Imatinib metabolite N-Desmethyl Imatinib; CGP 74588
N‑Desmethyl imatinib (Norimatinib) is an active metabolite of Imatinib (HY-15463), a selective c‑Abl inhibitor, and a substrate of P‑glycoprotein. N-Desmethyl imatinib binds to the c-Abl catalytic domain to prevent substrate phosphorylation, inhibits c-Abl-mediated α-synuclein activation and downstream inflammatory signaling pathways. N-Desmethyl imatinib induces apoptosis in K562 human leukemia cells. N-Desmethyl imatinib shows significantly elevated plasma levels in gastrointestinal stromal tumor (GIST) models with mild SARS-CoV-2 infection. N-Desmethyl imatinib can be used for the research of Parkinson’s disease, gastrointestinal stromal tumor, and chronic myeloid leukemia .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-15463S
CAS No.: 1092942-82-9
Purity:  99.85%
Synonyms: STI571-d8; CGP-57148B-d8
Imatinib-d8 is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-132386S
CAS No.: 1092942-83-0
Synonyms: STI571-d8 mesylate; CGP-57148B-d8 mesylate
Imatinib-d8 (mesylate) is the deuterium labeled Imatinib mesylate .
loading...
    loading...
Cat. No.: HY-15463S1
CAS No.: 1134803-16-9
Purity:  99.97%
Synonyms: STI571 d4; CGP-57148B d4
Imatinib-d4 (STI571-d4) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .
loading...
    loading...
Cat. No.: HY-W440982
CAS No.: 56421-10-4
Synonyms: PC(18:0/18:1); 2-Oleoyl-1-stearoyl-sn-glycero-3-phosphocholine
Target:  

Liposome

Research Areas:  

Others

SOPC (PC (18:0/18:1)) is a phosphatidylcholine lipid, which is an unsaturated phospholipid containing a cis double bond. When SOPC binds to Imatinib (HY-15463), Imatinib easily penetrates into its unsaturated liposome bilayer structure, and SOPC forms ordered, larger parallel stripe domains .
loading...
    loading...
Cat. No.: HY-W143698
CAS No.: 404844-11-7
Target:  

Bcr-Abl c-Kit PDGFR

Research Areas:  

Cancer

PDGFRα kinase inhibitor 2 (compound 1), an Imatinib (HY-15463) analogue, is a covalent and irreversible kinase inhibitor with IC50s of 6.95 μM, 2.45 μM, 1.39 μM for ABL1 wt, KIT wt, PDGFRR wt .
loading...
    loading...
Cat. No.: HY-164393
CAS No.: 1035199-04-2
Target:  

JAK Bcr-Abl Apoptosis

Research Areas:  

Cancer

ON044580 is a non–ATP-competitive JAK2 and BCR-ABL kinases inhibitor. ON044580 inhibits wild-type (WT) and V617F mutant JAK2 with IC50 values of 1.23 μM, 1.09 μM, respectively. ON044580 also inhibits both WT and T315I mutant BCR-ABL kinases., ON044580 blocks the IL-3–mediated phosphorylation of JAK2 and STAT5, induces apoptosis in Imatinib (HY-15463)-resistant chronic myeloid leukemia (CML). ON044580 can be used for the study of CML, myelodysplasia (MDS) and other myeloproliferative neoplasms .
loading...
    loading...
Cat. No.: HY-G0017S
CAS No.: 1185103-28-9
Synonyms: NorImatinib-d8; Imatinib metabolite N-Desmethyl Imatinib-d8; CGP 74588-d8
N-Desmethyl imatinib-d8 is a deuterium labeled Imatinib metabolite N-Desmethyl Imatinib (HY-G0017). N‑Desmethyl imatinib (Norimatinib) is an active metabolite of Imatinib (HY-15463), a selective c‑Abl inhibitor, and a substrate of P‑glycoprotein. N-Desmethyl imatinib binds to the c-Abl catalytic domain to prevent substrate phosphorylation, inhibits c-Abl-mediated α-synuclein activation and downstream inflammatory signaling pathways. N-Desmethyl imatinib induces apoptosis in K562 human leukemia cells. N-Desmethyl imatinib exhibits significantly elevated plasma levels in gastrointestinal stromal tumor (GIST) settings following mild SARS CoV 2 infection. N-Desmethyl imatinib can be used for the research of Parkinson’s disease, gastrointestinal stromal tumor, and chronic myeloid leukemia .
loading...
    loading...
Cat. No.: HY-15463R
CAS No.: 152459-95-5
Synonyms: STI571 (Standard); CGP-57148B (Standard)
Research Areas:  

Cancer

Imatinib (Standard) is the analytical standard of Imatinib. This product is intended for research and analytical applications. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
loading...
    loading...
Cat. No.: HY-50946R
CAS No.: 220127-57-1
Synonyms: STI571 Mesylate (Standard); CGP-57148B Mesylate (Standard)
Research Areas:  

Cancer

Imatinib (Mesylate) (Standard) is the analytical standard of Imatinib (Mesylate). This product is intended for research and analytical applications. Imatinib Mesylate (STI571 Mesylate) is an orally active tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.
loading...
    loading...
Cat. No.: HY-111849
CAS No.: 1436868-85-7
Synonyms: CGP-57148B carbaldehyde; STI571 carbaldehyde; PROTAC ABL binding moiety 1
Research Areas:  

Cancer

Imatinib carbaldehyde (CGP-57148B carbaldehyde), the Imatinib (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER .
loading...
    loading...
Cat. No.: HY-15463S3
Synonyms: STI571-13C,d3; CGP-57148B-13C,d3
Imatinib- 13C,d3 (STI571- 13C,d3) is 13C labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
loading...
    loading...
Cat. No.: HY-E70634
Target:  

Bcr-Abl

Research Areas:  

Cancer

The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 E255K Recombinant Human Active Protein Kinase is a recombinant ABL1 E255K protein that can be used to study ABL1 E255K-related functions .
loading...
    loading...
Cat. No.: HY-125090
CAS No.: 398493-74-8
PHA-680626 is an effective inhibitor of the interaction between Aurora-A and N-Myc. PHA-680626 inhibits kinase activity of AURKA and Bcr-Abl, and induces N-Myc degradation. PHA-680626 decreases phosphorylation of CrkL and histone H3. PHA-680626 shows anti-proliferative and pro-apoptotic activity on Imatinib (HY-15463)-resistant chronic myeloid leukemia cell lines and primary CD34+ cells .
loading...
    loading...
Cat. No.: HY-179247
Target:  

Bcr-Abl

Research Areas:  

Cancer

BCR-ABL1-IN-2 (compound 8) is a potent BCR-ABL1 tyrosine kinase inhibitor. BCR-ABL1-IN-2 exhibits activity in Imatinib (HY-15463) resistant K562/DOX cells with LC50 of 5.29 μM. BCR-ABL1-IN-2 shows no significant toxicity in nontumor cells. BCR-ABL1-IN-2 can be used for chronic myeloid leukemia research .
loading...
    loading...
Cat. No.: HY-G0017A
CAS No.: 404844-03-7
Synonyms: NorImatinib mesylate; Imatinib metabolite N-Desmethyl Imatinib mesylate; CGP 74588 mesylate
N-Desmethyl imatinib mesylate (Norimatinib mesylate) is an active metabolite of Imatinib (HY-15463), a selective c‑Abl inhibitor, and a substrate of P‑glycoprotein. N-Desmethyl imatinib mesylate binds to the c-Abl catalytic domain to prevent substrate phosphorylation, inhibits c-Abl-mediated α-synuclein activation and downstream inflammatory signaling pathways. N-Desmethyl imatinib mesylate induces apoptosis in K562 human leukemia cells. N-Desmethyl imatinib mesylate exhibits significantly elevated plasma levels in gastrointestinal stromal tumor (GIST) settings following mild SARS CoV 2 infection. N-Desmethyl imatinib mesylate can be used for the research of Parkinson’s disease, gastrointestinal stromal tumor, and chronic myeloid leukemia .
loading...
    loading...